## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.41 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($215.50)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Assessing AbbVie’s (ABBV) Valuation After New Cancer Data, EPKINLY Approval, and Dividend Hike**
- Source: Simply Wall Street | 20251204T015813 | Bullish | Relevance: 100%
- This article assesses AbbVie's (ABBV) valuation following recent positive catalysts, including new cancer data, FDA approval for EPKINLY, and a dividend hike. It explores whether the market has already priced in these developments, concluding that AbbVie appears modestly undervalued based on a projected profitability reset despite its significant year-to-date share price increase and strong long-term performance. The analysis also considers the company's price-to-sales ratio relative to peers and fair value.

**2. AbbVie Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163100 | Bullish | Relevance: 100%
- Shares of AbbVie Inc. (ABBV) rose 2.62% to $230.24 on Wednesday, outperforming the broader market. This gain broke a two-day losing streak for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw increases.

**3. AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers**
- Source: Investing News Network | 20251203T002136 | Bullish | Relevance: 100%
- AbbVie (NYSE: ABBV) announced it will present new data at the 2025 American Society of Hematology (ASH) Congress, highlighting advancements in treating multiple blood cancers with novel therapeutic modalities. Key presentations will feature investigational compounds etentamig and PVEK, alongside approved therapies EPKINLY® and VENCLEXTA®, demonstrating promising efficacy and safety profiles across various hematologic malignancies. The data reinforces AbbVie's leadership in oncology and commitment to improving care standards for patients with difficult-to-treat blood cancers.

**4. M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251205T190730 | Bullish | Relevance: 100%
- M Holdings Securities Inc. significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 68.6% in the second quarter, bringing its total holdings to 16,979 shares valued at $3.12 million. This move comes as AbbVie reported strong Q3 results, beating earnings estimates and raising its quarterly dividend. The company also received positive sentiment from Wall Street analysts, with an average "Moderate Buy" rating.

**5. AbbVie Inc. $ABBV Shares Bought by Brown Advisory Inc.**
- Source: MarketBeat | 20251205T180716 | Bullish | Relevance: 100%
- Brown Advisory Inc. increased its stake in AbbVie Inc. by 3.6% during the second quarter, bringing its total holdings to 868,648 shares worth over $161 million. Other institutional investors like Norges Bank, Nuveen LLC, and Vanguard Group Inc. also made significant buys, pushing total institutional ownership to 70.23%. AbbVie reported strong Q3 earnings, beating analyst estimates with an adjusted EPS of $1.86 and revenue of $15.78 billion, and announced a quarterly dividend increase to $1.73.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-07 | UBS | $220 | $195 | +13% |
| 2025-11-05 | Piper Sandler | $289 | $284 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-07 | UBS | main | Neutral |
| 2025-11-05 | Piper Sandler | reit | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 15.9x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $406.5B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 15.9 |
| Current P/E | 21.2 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -1.8% to -3.5% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.52), momentum weakening. RSI neutral at 48. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.53% (CS: 24) | Weak |
| RSI_14 | 47.8 | Neutral |
| MACD Histogram | -0.52 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 1.105x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $226.08
- **Stop Loss:** $215.50 (4.7% risk)
- **Target:** $247.24 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $10,625.76
- **Portfolio %:** 10.63%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*